NCT06522581|UnknownPhase 1
Loading search results
Sponsor study identifier
interventional
200
1 country
1
Study Start
January 1, 2024
Actual (reported)Primary Completion
January 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Hypoxic ischemic encephalopathy is an acute or subacute brain injury, due to asphyxia in neonates, leading to mortality and long-term morbidity. Its prevalence varies across regions, with developed countries reporting rates of 1.5 per 1000 live births, while developing nations experience a wider range from 2.3 to 26.5 per 1000 live births. Infants afflicted with moderate HIE face a 10% risk of mortality, with surviving individuals encountering a 30% chance of developing disabilities. The prognosis is graver for severe HIE, with a mortality risk of 60%, and nearly all survivors experiencing some form of disability.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2024
Actual (reported)July 22, 2024
Actual (reported)July 26, 2024
Actual (reported)January 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
survival in newborn babies with HIE
we will be evaluationg the efficacy of citicoline in newborns with HIE
one year after the start of study
this arm will include neonates suffering from hypoxic ischemic encephalopathy and who will be given injection citicoline
this arm will include neonates who will be suffering from HIE but will recieve rotuine care in NICU but will not receive injection citicoline
one group of neonates with confirmed HIE grade II and III will receive injection citicoline through IV route within 06 hours of birth
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
MH
Rawalpindi, 68000, Pakistan
arshad Khushdil, FCPS
PEMH
First Submitted
July 22, 2024
First Posted
July 26, 2024
Study Start
January 1, 2024
Actual (reported)Primary Completion
January 1, 2025
Estimated (date passed)Continuous Versus Bolus Feeding in Neonates With Hypoxic Ischemic Encephalopathy
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 14, 2024
Record last verified: 2024-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: